This study is comparing two anti-clotting medications, ticagrelor (90 mg) and prasugrel (10 mg), when used alone after a procedure called PCI (percutaneous coronary intervention) for coronary artery disease. If you've been on dual antiplatelet therapy (DAPT) with aspirin plus either prasugrel or ticagrelor for at least 90 days after PCI, and are between 18 and 75 years old, you might be able to join. The study wants to see if these two medications, when used alone, have similar effects on your platelets (tiny blood cells involved in clotting). The goal is to determine if prasugrel monotherapy is as effective as ticagrelor monotherapy in controlling platelet activity. The current status of this study is unclear, and it plans to enroll 48 participants.

Study design

This is an interventional study where participants will be randomly assigned to receive either ticagrelor or prasugrel monotherapy. It plans to enroll 48 participants.

What's involved

After providing consent, you would stop taking aspirin and be assigned to take either ticagrelor 90 mg twice a day or prasugrel 10 mg once a day. Platelet reactivity will be measured around 21 days later.

Compensation

Not stated in the trial record.

Follow-up

Platelet reactivity will be measured at 21 ± 7 days after starting the new medication.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.